EF Hutton Initiates Coverage On Trevi Therapeutics with Buy Rating, Announces Price Target of $21
Portfolio Pulse from Benzinga Newsdesk
EF Hutton has initiated coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Buy rating and set a price target of $21.
August 19, 2024 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton has initiated coverage on Trevi Therapeutics with a Buy rating and a price target of $21.
The initiation of coverage with a Buy rating and a price target of $21 by EF Hutton is likely to positively impact Trevi Therapeutics' stock price in the short term. Analyst ratings and price targets are significant indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100